Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)vsAstraZeneca PLC (AZN)
AMRX
Amneal Pharmaceuticals, Inc. Class A Common Stock
$17.01
+0.83%
HEALTHCARE · Cap: $6.01B
AZN
AstraZeneca PLC
$160.17
+0.33%
HEALTHCARE · Cap: $252.33B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 1868% more annual revenue ($61.37B vs $3.12B). AZN leads profitability with a 17.0% profit margin vs 5.0%. AZN trades at a lower P/E of 24.3x. AZN earns a higher WallStSmart Score of 60/100 (C+).
AMRX
Buy56
out of 100
Grade: C
AZN
Buy60
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+28.5%
Fair Value
$20.56
Current Price
$17.01
$3.55 discount
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 157.1% YoY
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Areas to Watch
Premium valuation, high expectations priced in
5.0% margin — thin
Trading at 170.1x book value
ROE of -881.0% — below average capital efficiency
2.5% earnings growth
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AMRX
The strongest argument for AMRX centers on EPS Growth.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bear Case : AMRX
The primary concerns for AMRX are P/E Ratio, Profit Margin, Price/Book. Debt-to-equity of 84.54 is elevated, increasing financial risk.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
AMRX profiles as a value stock while AZN is a mature play — different risk/reward profiles.
AMRX carries more volatility with a beta of 1.24 — expect wider price swings.
AMRX is growing revenue faster at 9.9% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 56/100), backed by strong 17.0% margins. AMRX offers better value entry with a 28.5% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amneal Pharmaceuticals, Inc. Class A Common Stock
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Amneal Pharmaceuticals, Inc. develops, licenses, manufactures, markets and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company is headquartered in Bridgewater, New Jersey.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?